Although it may not be effective in a tumor microenvironment dominated by immunosuppressive cell types, this strategy is still promising as a follow-up treatment where tumor-associated cDC1 may be harvested from primary tumor tissue after an operation, requiring a much lower number of cells than similar DC studies (104 cells as opposed to 105–3 × 106 cells) [103]. The gene discussed is MPPE1; the disease is neoplasm.